J Physiol Society Meetings
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Physiol Volume 586, Number 16, 3855-3869, August 15, 2008 DOI: 10.1113/jphysiol.2008.153593
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
586/16/3855    most recent
jphysiol.2008.153593v1
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Lu, R.
Right arrow Articles by Toro, L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, R.
Right arrow Articles by Toro, L.
Related Collections
Right arrow Cardiovascular

CARDIOVASCULAR

c-Src tyrosine kinase, a critical component for 5-HT2A receptor-mediated contraction in rat aorta

Rong Lu1, Abderrahmane Alioua1, Yogesh Kumar1, Pallob Kundu1, Mansoureh Eghbali1, Noelia V. Weisstaub2, Jay A. Gingrich2, Enrico Stefani1,3,5 and Ligia Toro1,4,5

1 Department of Anaesthesiology, Division of Molecular Medicine
3 Department of Physiology
4 Department of Molecular & Medical Pharmacology
5 Brain Research Institute and Cardiovascular Research Laboratory, University of California, Los Angeles, Los Angeles, CA 90095, USA
2 Department of Psychology and the Sackler Institute of Developmental Neuroscience, Columbia University and the New York State Psychiatric Institute, New York, NY 10032, USA

Serotonin (5-hydroxytryptamine, 5-HT) receptors (5-HTRs) play critical roles in brain and cardiovascular functions. In the vasculature, 5-HT induces potent vasoconstrictions, which in aorta are mainly mediated by activation of the 5-HT2AR subtype. We previously proposed that one signalling mechanism of 5-HT-induced vasoconstriction could be c-Src, a member of the Src tyrosine kinase family. We now provide evidence for a central role of c-Src in 5-HT2AR-mediated contraction. Inhibition of Src kinase activity with 10 µM 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) prior to contraction resulted in ~90–99% inhibition of contractions induced by 5-HT or by {alpha}-methyl-5-HT (5-HT2R agonist). In contrast, PP2 pretreatment only partly inhibited contractions induced by angiotensin II and the thromboxane A2 mimetic, U46619, and had no significant action on phenylephrine-induced contractions. 5-Hydroxytryptamine increased Src kinase activity and PP2-sensitive tyrosine-phosphorylated proteins. As expected for c-Src identity, PP2 pretreatment inhibited 5-HT-induced contraction with an IC50 of ~1 µM. Ketanserin (10 nM), a 5-HT2A antagonist, but not antagonists of 5-HT2BR (100 nM SB204741) or 5-HT2CR (20 nM RS102221), prevented 5-HT-induced contractions, mimicking PP2 and implicating 5-HT2AR as the major receptor subtype coupled to c-Src. In HEK 293T cells, c-Src and 5-HT2AR were reciprocally co-immunoprecipitated and co-localized at the cell periphery. Finally, 5-HT-induced Src activity was unaffected by inhibition of Rho kinase, supporting a role of c-Src upstream of Rho kinase. Together, the results highlight c-Src activation as one of the early and pivotal mechanisms in 5-HT2AR contractile signalling in aorta.

(Received 6 March 2008; accepted after revision 25 June 2008; first published online 3 July 2008)
Corresponding author L. Toro: Department of Anaesthesiology, UCLA School of Medicine, BH-509A CHS, Box 957115, Los Angeles, CA 90095-7115, USA.  Email: ltoro{at}ucla.edu


R. Lu and A. Alioua contributed equally to this work.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 The Physiological Society.